Business Standard

Thursday, December 19, 2024 | 08:06 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday

Dr Reddy's
Premium

The North America business has declined 11 per cent sequentially due to price erosion

Sohini Das Mumbai
Hyderabad-based Dr Reddy’s Laboratories (DRL) has posted a sharp 108 per cent YoY rise in its Q1FY23 profit after tax -- which came in at Rs 1,188 crore -- riding on strong growth in its India business. The revenue for the June quarter was up 6 per cent to Rs 5,215 crore.

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday. The company’s India business grew by 26 per cent YoY to Rs 1,333.9 crore. This was driven by the divestment of a few non-core brands, the company said.

M V Ramana,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in